Immune checkpoint inhibitors (ICIs), including anti‐programmed‐cell death‐1 (PD‐1) and anti‐PD‐ligand 1 (PD‐L1) antibodies, have demonstrated promising and durable benefits in non‐small‐cell lung cancer (NSCLC) patients.1, 2, 3, 4, 5 Anti‐PD‐1 and anti‐PD‐L1 antibodies have become the new standard of care for NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.